Trials in Illinois.
76 APOE4-relevant Alzheimer’s trials run in Illinois — 35 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Open to carriers, genotype not consideredNCT02525198The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial
This trial is testing a dietary supplement that combines fatty acids (like omega-3s) and flavonoids (plant-based compounds) to see whether the combination…
- Open to carriers, not 4-specificNCT02814526Exercise in Adults With Mild Memory Problems
This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Cancer patients only, genotype not specifiedNCT03016741Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This trial is studying whether prostate cancer hormone therapies — specifically abiraterone acetate and enzalutamide — affect brain structure and cognitive…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Not relevant to APOE4 carriersNCT03836950rTMS to Improve Cognition in Parkinson's
This trial is testing repetitive transcranial magnetic stimulation, or rTMS, a non-invasive device that delivers magnetic pulses to the brain, to see whether…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- General planning study, not genotype-specificNCT03960476Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
This study is testing a website called PlanYourLifespan.org to understand how older adults make long-term care and aging-in-place decisions. Researchers want…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Device study, genotype not consideredNCT04240561Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
This trial is testing two different hearing aid signal processing approaches in older adults who have Alzheimer's dementia or amnestic mild cognitive…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- Observational ICU study, not genotype-relevantNCT04305600Bringing to Light the Risk Factors And Incidence of Neuropsychological Dysfunction in ICU Survivors, 2nd Study
This study is tracking ICU survivors over time to understand why some people develop lasting cognitive problems after critical illness. Researchers are…
- Lifestyle study, genotype not requiredNCT04337255Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
This trial tests whether following the MIND diet for two to three years after a stroke slows cognitive decline compared to standard post-stroke dietary care.…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Detection tool, genotype not a factorNCT04852601ToolBox Detect: Low Cost Detection of Cognitive Decline in Primary Care Settings
This trial is testing a digital screening tool called ToolboxDetect, designed to help primary care doctors spot early cognitive decline more easily during…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Open to MCI; genotype not a factorNCT04938349Dual Task Perturbation Training for OAwMCI
This trial tests a specialized treadmill training program for older adults with mild cognitive impairment (MCI). A motorized treadmill delivers sudden balance…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- Not relevant to APOE4 carriersNCT05184569Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
This Phase 1 trial is testing whether verdiperstat, a drug that may reduce harmful inflammation in brain cells, is safe and tolerable for people with semantic…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05511363A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…
- Open to carriers, not 4-specificNCT05531656A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
This trial is testing CT1812, an experimental drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia confirmed by…
- Familial mutation only, not APOE4NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2)…
- Detection study, genotype not consideredNCT05607732Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
This trial is testing a digital screening tool called MyCog, built on the NIH Toolbox, to see whether primary care clinics can reliably catch early cognitive…
- Not relevant to APOE4 or Alzheimer'sNCT05686551GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is…
- Open to carriers, not 4-specificNCT05811338Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1
This trial is testing a virtual reality program called CAST, designed to give older adults with mild cognitive impairment a way to stay socially connected,…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Open to carriers, not 4-specificNCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…
- Open to carriers, genotype not requiredNCT06112860OTC Hearing Aid and MCI
This trial is testing whether over-the-counter hearing aids improve communication in people who already have mild cognitive impairment or early dementia and…
- Open to carriers, not 4-specificNCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This Phase 3 trial is testing KarXT, a drug that targets muscarinic receptors in the brain, against a placebo in people aged 55 to 90 who have Alzheimer's…
- Not Alzheimer's focused, genotype irrelevantNCT06191198Communication Bridge 3 Study
This Phase 2 trial is comparing two speech-language therapy approaches for people with mild to moderate Primary Progressive Aphasia, a condition that gradually…
- Not APOE4-focused, PPA patients onlyNCT06211374Communication Bridge Pilot Study
This trial is testing a web-based communication program called Communication Bridge, designed specifically for people with primary progressive aphasia (PPA) —…
- Open to carriers, not 4-specificNCT06223360A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…
- Open to carriers, not 4-specificNCT06254469Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
This trial is testing a new PET scan tracer called F-18 Flornaptitril to see how well it can predict cognitive decline in people who already have Mild…
- Open to carriers, not 4-specificNCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…
- Open to carriers, genotype not trackedNCT06307574bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
This trial is testing a smartphone app designed to help older adults with mild cognitive impairment stick to their blood pressure medications. One group gets…
- Behavioral study, genotype not a factorNCT06330844Race-Based Stress and Cognitive Training for MCI
This trial is testing a new group therapy program for older Black and African American adults with mild cognitive impairment (MCI). The program blends…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.